Chapter 95: Antimycobacterial Agents: Drugs for Tuberculosis

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about treating a bacterial infection, there's this expectation of rapid precision,

like, I don't know, like putting out a small campfire.

Right, yeah.

You take your 10 -day course of some broad -spectrum antibiotic and that's it.

Exactly.

The bacteria are wiped out, the symptoms vanish, and the doctor just points to your chart and says,

you know, there it is, you're cured.

It feels completely binary, like you're sick and then you're not sick.

A very clean, predictable timeline.

It's comforting.

We like things to be quick, easily categorized and just, well, eliminated.

But then you step into the world of mycobacteria and suddenly that trusty fire extinguisher is totally useless.

You're looking at a pharmacological landscape that is, honestly, an absolute marathon.

Oh, absolutely.

And that marathon is exactly why you asked us to dive into Chapter 95 of Lens Pharmacology today.

The last -minute lecture team is here to help you master anti -mycobacterial agents so you can ace your exam on tuberculosis or TB.

Yeah, this disease is the absolute definition of a therapeutic long game because while we often associate tuberculosis with historical dramas or, I don't know, Victorian novels,

it remains a staggering global health crisis today.

It really does.

I mean, the World Health Organization estimates that 10 million people become infected every single year, resulting in like 1 .5 million deaths.

Wow.

1 .5 million deaths a year for something we have drugs for sounds incredibly bleak.

But the text does actually give you a silver lining right out of the gate.

It does, yeah.

If you look at Figure 95 .1 in the chapter, the global TB death rate has actually dropped 22 % in the last 15 years.

And here in the U .S., new cases have been steadily declining for decades.

So our pharmacological strategies are working.

We just, you know, we can't take our foot off the gas.

Right.

And to understand the sheer length of that timeline we mentioned, you have to really understand the enemy itself.

Mycobacteria are what we call acid -fast microbes.

Which basically means they resist being decolorized by the dilute acid used in laboratory staining, right?

Exactly.

But clinically speaking, their most defining feature is that they are incredibly slow growing, like very slow.

Conventional antibiotics generally work by attacking rapidly dividing cells.

So because mycobacteria divide so slowly, they essentially just fly under the radar of our standard medications.

They just hide.

Yeah, they do.

So treatment has to be massively prolonged.

We're talking six months to two years or even more in some cases.

And that prolonged timeline creates the two biggest hurdles in TB pharmacology, which are severe drug toxicity and poor patient adherence.

I mean, taking intense medications for two weeks is one thing, but taking them for a year?

It's a totally different ballgame.

Yeah.

So to understand how these drugs actually do their job, we first need to understand how TB behaves in the body.

The infectious process starts when someone inhales aerosolized sputum.

Usually from a cough or a sneeze?

Right.

That contains mycobacterium tuberculosis.

And once inhaled, those tubercle bacillus travel deep into the lungs where they are swallowed up by phagocytic macrophages and neutrophils.

But here is the wild part.

In about 90 % of cases, the body's immunity develops within a few weeks.

The immune system essentially walls off the bacteria, bringing the infection under control.

So it's contained.

Right.

Exactly.

This is a latent infection.

The person has zero symptoms and their chest x -ray might even look perfectly normal, save for maybe some minor fibrotic changes.

I always like to think of a latent TB infection as a sleeper agent.

Oh, that's a great way to put it.

The person doesn't feel sick at all, but they are harboring these quiescent, totally dormant bacteria inside their cells for life.

And the text points out that in 5 % to 10 % of those people,

those sleeper agents reactivate.

Yeah.

If the immune system fails to control that primary infection or if it weakens later in life due to age or illness, the sleeper agents wake up and active clinical TB develops.

Which is when it gets really destructive.

Extremely.

This leads to severe tissue necrosis and cavitation in the lungs.

The lung tissue can actually become caseous, which is a clinical term meaning cheese -like in appearance.

Oh, gross.

Yeah, the bacteria are quite literally liquefying the lung tissue, so this biological dynamic dictates our entire pharmacological strategy.

Treatment must be capable of killing the actively dividing bugs out in the open while also hunting down those dormant intracellular sleeper agents.

So we have stubborn, slow -growing bacteria that like to hide inside our own cells.

And the text makes a huge point about drug resistance, which is scary.

It defines MDRTB, which is multi -drug -resistant TB.

That means the bug is resistant to our two absolute best drugs, isoniazid and rifampin.

Then there's XDRTB, extensively drug -resistant TB, which adds resistance to fluoroquinolones and at least one of our injectable second -line drugs.

You know, the financial cost of that resistance is just staggering.

Treating normal, susceptible TB costs about $20 ,000.

Eradicating XDRTB requires a brutal 32 -month regimen and costs an average of over $567 ,000.

Half a million dollars.

That is insane.

It is.

And that massive discrepancy brings us to a major clinical rule for your nursing practice, the prime directive of TB therapy.

Always treat active TB with two or more drugs.

Never ever use just one.

Wait, let me push back on that for a second.

Because in previous chapters, Lenz explicitly warned us that using multiple broad -spectrum antibiotics at the same time is exactly what causes super infections.

It's true.

It did.

Like, we wipe out the good gut bacteria and the bad ones take over, like C.

diff.

So why doesn't that happen here with KB when we throw four drugs at a patient all at once?

That is a really crucial distinction to make.

What's fascinating here is that these major anti -TB drugs are highly, highly selective for mycobacterium tuberculosis.

They target structural components or enzymes that are entirely unique to mycobacteria.

Okay.

Yeah.

Because they are so hyper -focused, they don't indiscriminately wipe out the body's normal beneficial flora in the GI tract.

So the ecological vacuum that usually leads to super infection simply isn't created even with a four -drug cocktail.

That is such an elegant design.

So because of that resistance risk, we use very specific multi -drug regimens over long periods.

The standard treatment for drug -susceptible TB is basically divided into two phases.

Right.

Intensive and continuation.

Yeah.

First, you have the intensive phase, which lasts about eight weeks.

The goal here is to aggressively eliminate the actively dividing extracellular bacilli.

Then you step down to the continuation phase for 18 weeks, which is all about hunting down those persistent intracellular sleeper agents.

And that standard six to nine month regimen uses four first -line drugs during the intensive phase.

Isoniazid, rifampin, pyrazenomide, and ethambutil.

The big four.

Exactly.

Then for the continuation phase, you drop the last two and just continue with Isoniazid and rifampin.

The text also highlights a new alternative four month regimen endorsed by the CDC.

This uses high -dose rifapentine, moxafloxacin, isoniazid, and pyrazenomide.

It's purring to be highly effective and shaves months off the treatment time, which massively improves adherence.

We also have to talk about special populations because TB doesn't care if a patient is pregnant or dealing with other health issues.

For pregnant patients, the CDC states that the benefits of isoniazid, rifampin, and pyrazenomide justify the risks, but ethambutil is teratogenic in animal studies.

Right.

That's a much tougher risk -benefit conversation.

Exactly.

Then there are patients with HIV.

Between 2 % and 20 % of patients with HIV actually develop active TB.

Yeah.

Managing TB in a patient with HIV is an incredibly complex pharmacological balancing act.

HIV patients require much longer TB treatment, sometimes up to 30 months, but rifampin, which is the absolute cornerstone of TD therapy, accelerates the metabolism of most protease inhibitors and non -nucleoside reverse transcriptase inhibitors used to treat HIV.

So it basically forces the liver to destroy the HIV medications before they can even work.

Precisely.

If they take rifampin, their HIV meds just stop working.

So often, providers will substitute a drug called rifabutin instead of rifampin because it has far less impact on those antiretroviral levels.

Right.

So all of this brings us to what might be, honestly, the most vital nursing application in the entire chapter.

The number one cause of treatment failure, relapse, and increased drug resistance isn't the drugs failing.

No, it's not.

It's patient non -adherence.

I mean, think about it.

If a patient is supposed to take four heavy -duty medications that make them feel awful every single day for six months,

it's just basic human nature to want to stop taking them the minute their cough goes away.

Oh, absolutely.

And this is the exact reason we use DOT, or directly observed therapy.

It's often combined with intermittent dosing, like giving the drugs two or three times a week rather than every single day just to make the regimen more manageable.

Under DOT, a representative of the health department, or a nurse,

physically watches the patient swallow every single dose.

Wait, DOT, you mean a nurse literally watches them swallow a pill every day for six months?

Yes.

That sounds like a policing action.

How does a patient even agree to that?

And isn't it a massive drain on nursing resources?

Well, it sounds restrictive, sure, but DOT is actually the standard of care because it serves a dual purpose.

It ensures adherence, yes, but more importantly, it allows the nurse to perform ongoing clinical evaluation.

You aren't just making sure the pill goes down the hatch.

You are physically assessing the patient two to three times a week.

Oh, that makes total sense.

Yeah, you can catch adverse effects like early signs of liver failure before they become life -threatening.

So you're turning a medication pass into a continuous assessment.

That's really smart.

So if treating active TB is this intense, we absolutely need a way to catch and treat it while it's still latent.

Definitely.

And testing for latent TB infection, or LTBI, relies on two main methods.

The traditional method is the TST, the tuberculin skin test, which uses a purified protein derivative, or PPD.

You inject it intradermally.

Right, the little bubble under the skin.

Yeah.

If the patient has an intact immune system and has been exposed to TB in the past, they will mount a local immune response.

The nurse then reads the test 48 to 72 hours later by measuring the endoration, which is the hard raised bump, not just the red area around it.

And interpreting that endoration is a classic exam topic.

Table 95 .3 breaks it down beautifully by risk category.

And the logic behind it is just fascinating.

You don't just look for a universal bump size.

A five millimeter bump, which is tiny, is considered positive if the patient is high risk, like someone who is HIV positive.

Right.

And why is that?

Because their compromised immune system isn't strong enough to mount a massive reaction.

If they show even a five millimeter response, it's a huge red flag that they've been exposed.

Exactly.

On the other hand, you need a 10 millimeter endoration to be considered positive for a moderate risk patient, like an IV drug user or a nursing home resident.

And for a low risk person with a healthy immune system and no known exposure, they are capable of a really strong defense.

So the bump needs to be a full 15 millimeters to be considered a true positive.

That is such a good way to remember it.

Now, alongside the TST, we now have IGRAs, Interferon Gamma Release Assays.

These are blood tests that measure the release of Interferon Gamma by the patient's white blood cells when exposed to TB antigens.

They are faster, they don't cross react with other vaccines, and they don't require the patient to come back in 48 hours for a reading.

Which is a huge plus for adherence.

Oh, massive.

But regardless of how you'd test, the text stresses a critical safety checkpoint here.

Active TB must be completely ruled out with a physical exam and a chest x -ray before you treat latent TB.

Yes, the pharmacological reasoning there is absolute.

Latent TB is treated with just one or two drugs rather than the full four drug intensive cocktail.

If a patient actually has active TB and you mistakenly treat them with a latent one or two drug regimen, you're applying just enough pressure to kill the weak bacteria while allowing the strong ones to mutate.

You're essentially guaranteeing the creation of a drug resistant superbug.

Precisely.

You never want to do that.

So if active TB is ruled out, the latent regimens include options like Isonia Z and Rifapentine taken weekly for three months, or Rifapin taken daily for four months.

And just a quick note on the vaccine, the BCG vaccine is used globally, but the US doesn't routinely use it because our endemic risk is low and the protection it offers in adulthood is, well, highly variable.

Yeah, plus getting the vaccine can trigger a false positive on that TST skin test we just talked about.

Right.

So we've covered the pathogenesis and the regimens.

Now we need to dive into the core pharmacology of chapter 95, the big four first line drugs.

We need to systematically break these down so you know exactly how they work and what safety alerts to monitor.

And the anchor of all TB therapy is Isoniazid, often abbreviated as INH.

Right.

And the mechanism of action for Isoniazid is incredibly targeted.

It suppresses bacterial growth by inhibiting the synthesis of mycolic acid.

Which is a unique vital component of the mycobacterial cell wall, right?

Exactly.

Because human cells and normal gut bacteria don't make mycolic acid, Isoniazid leaves our normal cells alone.

But the adverse effects are significant, the most dangerous being hepatotoxicity.

So liver damage is the primary concern.

Yes, Isoniazid can cause hepatocellular injury and even fatal multilocular necrosis.

And the greatest risk factor here isn't necessarily the dose, it's actually advancing age.

The risk is extremely low in patients under 20, but it climbs to about 8 % in patients over 65.

As a nurse, you must monitor AST levels and teach patients the clinical signs of liver damage.

Anorexia, malaise, fatigue, and jaundice.

You know, the yellowing of the skin or eyes.

And the other major adverse effect of Isoniazid is dose -related peripheral neuropathy.

Patients will complain of tingling, numbness, burning, or pain in their hands and feet.

Yeah, and the why behind this is fascinating.

It really is.

Isoniazid structurally resembles vitamin B6, also known as pyridoxine.

The drug actually competes with vitamin B6 and promotes its excretion.

So the patient's nerves are literally starving for B6, which they desperately need to maintain healthy myelin sheaths.

So the specific nursing fix is to give pyridoxine at 25 to 50 milligrams a day to prevent the damage, or up to 100 milligrams to treat it once it starts.

We also have to look at how Isoniazid interacts with the liver enzymes.

Isoniazid is a strong cytochrome P450 inhibitor.

By inhibiting those liver enzymes, it stops the breakdown of other drugs, dangerously raising their levels in the blood.

Like phenytoin.

Right.

Yes, exactly.

The classic example the text gives is phenytoin, a seizure medication.

If a patient is on both, the nurse must monitor for signs of phenytoin toxicity, like ataxia and in coordination, and the phenytoin dose will likely need to be reduced.

So Isoniazid shuts down the liver's ability to clear other drugs.

It's an inhibitor.

But if a patient is on a multi -drug regimen, how do we balance that?

Well, we bring in the second drug, rifampin, which acts as a biological opposite in the liver.

It does.

Rifampin inhibits bacterial DNA -dependent RNA polymerase, so it suppresses RNA synthesis and therefore protein synthesis.

It's highly lipid soluble, which is how it easily slips inside our host macrophages to kill those dormant sleeper agents.

Like Isoniazid, rifampin carries a risk of hepato -coxicity, especially in patients with pre -existing liver disease or heavy alcohol use.

But it has a very unique, albeit harmless side effect that you absolutely must educate your patients about.

Rifampin frequently imparts a bright red -orange color to bodily fluids, urine, sweat, saliva, and tears.

Yeah, tell your patients about this immediately or they will panic and think they are urinating blood.

Seriously.

And crucially, remind them to stop wearing soft contact lenses because those red -orange tears will stain their expensive contacts permanently.

Good tip.

But getting back to the liver interactions.

While Isoniazid is an inhibitor, rifampin is a powerful CYP450 inducer.

It kicks those exact same liver enzymes into overdrive.

Right.

It accelerates the metabolism of other medications, meaning those drugs are cleared from the body way too fast to be effective.

This is incredibly dangerous for patients on warfarin who may suddenly lose their anticoagulant protection and require higher doses.

It's also devastating for oral contraceptives.

Patients must be taught to use a non -hormonal backup method of birth control.

And as we mentioned earlier, it rapidly metabolizes HIV protease inhibitors.

So we have an inhibitor and an inducer creating a massive tug of war in the liver.

What else were we throwing at the patient during that intensive phase?

Yeah.

Drug number three, pyrazenomide.

Yes.

The full mechanism isn't entirely understood, but we know it's metabolized into pyrazenoic acid.

How does it kill dormant bugs?

Well, the sleeper agents hide inside macrophage compartments called which are naturally very acidic.

Pyrazenomide actually needs that acidic environment to convert into its active form.

It drops the pH even lower, essentially weaponizing the bacteria's own hiding spot until it becomes lethal.

Which is brilliant, honestly.

The standout fact for pyrazenomide, however, is that it is the most hepatotoxic of all the first line drugs.

It also inhibits the renal excretion of uric acid.

This causes hyperuricemia, leading to

So that's three highly liver toxic drugs so far.

We need a fourth for the intensive phase to prevent resistance.

Does it also attack the liver?

Thankfully, no.

The fourth drug is ethambutol.

Unlike the first three, ethambutol is bacteriostatic.

Meaning it suppresses growth rather than killing the bacteria outright.

Exactly.

It does this by inhibiting an enzyme

urbinosal transferase, which the bacteria need to build their cell walls.

But the critical safety alert for ethambutol isn't the liver, it's the eyes.

It causes optic neuritis.

The drug affects the optic nerve, leading to blurred vision, constriction of the visual field, and a very specific disturbance in red -green color discrimination.

And that visual change is exactly why ethambutol is generally not recommended for children under eight years old.

I mean, a five -year -old simply doesn't have the developmental ability to accurately report, excuse me, my red -green color discrimination seems slightly off today.

No, they really don't.

So let me synthesize this intensive phase for you as a student, because there is a massive clinical takeaway here.

Isoniazid is hepatotoxic.

Rifampin is hepatotoxic.

Piazinamide is the most hepatotoxic.

And you are administering them all to the patient at the exact same time.

It's a lot for the body to handle.

It is.

No wonder baseline liver function tests and continuous liver monitoring are the central pillars of a TB nursing care plan.

It really is the ultimate clinical balancing act of efficacy versus toxicity.

But what happens when these four drugs fail?

Yeah, that's the scary part.

If we are dealing with MDR or XDR -TB, we have to bring in the second -line agents.

These drugs are generally less effective, much more expensive, and significantly more toxic.

For instance, the fluoroquinolones like liamofloxacin and moxifloxam.

They cause severe GI intolerance and carry an FDA black box warning for tendon rupture, which can be permanent, especially in older adults.

Oh, wow.

Then you have the injectable second -line drugs capreomycin and the aminoglycosides amicusin and streptomycin.

The text has a giant safety alert for these.

They are heavily nephrotoxic, so they damage the kidneys.

But more uniquely, they are ototoxic.

Yeah, they physically damage the eighth cranial nerve, which is responsible for hearing and balance.

This can lead to profound permanent hearing loss and severe vertigo.

Which is life -altering.

And the text also highlights a relatively new addition to the arsenal, bedaquiline.

When the FDA granted accelerated approval for bedaquiline, it was massive news because it was the first completely new anti -TB drug mechanism to emerge in over 40 years.

Right.

And it works by inhibiting mycobacterial ATP synthase.

ATP is basically the energy currency of the cell.

Bedaquiline essentially cuts the power lines to the bacteria's energy factory.

And because humans produce ATP using a completely different enzymatic pathway, the drug doesn't shut down our own cellular energy.

Which is amazing.

Yeah.

But it is truly a drug of last resort.

It costs over $190 per pill, and it carries a terrifying black box warning.

It prolongs the QT interval on an EKG, delaying the heart's electrical reset cycle, which can trigger lethal ventricular dysrhythmias.

In the clinical trials, the group taking bedaquiline actually had an increased risk of death compared to the placebo group.

Wow.

Yeah.

You only deploy this weapon when you're completely out of other options.

So if we connect all of this pharmacology back to the bedside, how do you actually evaluate if this grueling multi -month goblet is working?

Evaluating success relies on three main timelines.

Clinically, you should see the fever, malaise, and cough start to reduce within a couple of weeks.

Radiographically, the chest x -rays should show clear improvement by the two -month mark.

And bacteriologically, the sputum culture should finally become negative between three and six months of therapy.

As for administration, teach your patients to take isoniazid on an empty stomach if possible, like one hour before or two hours after meals, to maximize absorption.

However, if severe GI upset occurs, it can be taken with meals.

And before any of this starts, your nursing assessment is rigorous.

You must obtain a baseline chest radiograph, a microbiologic sputum culture, and baseline liver function tests.

You also have to ask the hard questions during the intake history.

You must ask about alcohol use disorder.

Daily alcohol intake combined with isoniazid, rifampin, and pyrazinamide is just a recipe for sudden catastrophic liver failure.

You also have to assess for a history of diabetes because diabetic neuropathy compounded by isoniazid -induced B6 deficiency can leave a patient with severe permanent nerve damage in their extremities.

It really highlights that pharmacology isn't just memorizing drug classes, it's understanding how the drug interacts with the specific complex physiology of the patient sitting in front of you.

Absolutely.

And speaking of complex physiology, there is a chilling statistic in the text regarding the evolutionary arms race.

We are locked in with these microbes.

We talked about podacoline being the first new mechanism in 40 years targeting the bacteria's ATP synthase, but about one in 200 million tubercle bacilli already naturally produce an alternative form of ATP synthase that simply ignores the drug.

Yes,

they are naturally immune to our newest, most advanced weapon.

It begs a provocative question.

As we apply selective pressure with podacoline, how will the bacteria evolve next to secure their energy?

What completely unknown part of the bacterial anatomy will pharmacologists have to target 40 years from now just to keep pace?

That is wild to think about.

The bacteria are already holding the countermeasure before we even deploy the weapon.

It really proves that the fight against tuberculosis is far from over.

Well, that wraps up our deep dive into the source material for Chapter 95.

A huge thank you for letting the Last Minute Lecture team join your study session today.

You are the one who is going to be out there interpreting those TST indurations, monitoring those AST levels, pushing through the DOT hurdles, and keeping these patients safe.

Good luck in your pharmacology exams, good luck in your clinical practice, and we will catch you on the next deep dive.